Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial. Krilaviciute A, Kaaks R, Seibold P, de Vrieze M, et al. Eur Urol 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024.

Read + Share

Amedeo Smart

Independent Medical Education

Krilaviciute A, Kaaks R, Seibold P, de Vrieze M, et al. Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial. Eur Urol 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024.
PMID: 38749854